Khaja Asadullah, MD
Geriatric Medicine · Frankfort, ILNPI 1578515409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.
Across 91 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$196
- Johnson & Johnson$160
- Electromed, Inc.$145
- Amgen$99
- Novartis$80
- Pfizer$78
- plus $974 from 26 others
What the payments were for
- Food & beverage$1,732100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $196 |
| Johnson & Johnson | 6 | $160 |
| Electromed, Inc. | 8 | $145 |
| Amgen | 6 | $99 |
| Novartis | 5 | $80 |
| Pfizer | 4 | $78 |
| Abbott | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Corcept Therapeutics | 3 | $66 |
| Merz North America, Inc. | 1 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $48 |
| AbbVie(2 entities) | 2 | $47 |
| Shire North American Group Inc | 3 | $47 |
| Eisai Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Merck | 2 | $35 |
| AstraZeneca | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| Koya Medical, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Urovant Sciences Inc | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
How this compares
$1,732 in reported general payments places this provider in the 85th percentile of 147 geriatric medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,076 | $347,643 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $97,900 |
| JanuviaSitagliptin Phosphate | 148 | $61,823 |
| JardianceEmpagliflozin | 120 | $57,368 |
| EntrestoSacubitril/Valsartan | 116 | $49,442 |
| NuplazidPimavanserin Tartrate | 17 | $43,206 |
| XifaxanRifaximin | 29 | $41,190 |
| XareltoRivaroxaban | 97 | $37,957 |
| Invega SustennaPaliperidone Palmitate | 15 | $37,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $31,383 |
| TrulicityDulaglutide | 23 | $26,088 |
| LinzessLinaclotide | 42 | $24,627 |
| OzempicSemaglutide | 18 | $22,624 |
| Atorvastatin Calcium | 1,452 | $22,190 |
| TradjentaLinagliptin | 52 | $16,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $347,6431,076 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $160 | $75,742112 claims |
| MerckJanuvia | $35 | $61,823148 claims |
| NovartisEntresto | $80 | $49,442116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $72 | $41,19029 claims |
| AbbVieLinzess, Vraylar | $47 | $36,12458 claims |
| AstraZenecaBrilinta, Breztri Aerosphere, Farxiga | $32 | $30,89179 claims |
| Lilly USA, LLCTrulicity | $48 | $26,08823 claims |
| Novo NordiskOzempic | $196 | $22,62418 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $8,81432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 147 geriatric medicine providers in Illinois.
Other geriatric medicine in Frankfort
- Michael LimArlington Heights$29K
- Hima AtluriDecatur$21K
- Carlos Mella-PicelChicago$9K
- Rekha SharmaHazel Crest$8K
- Beata StykaPalos Heights$6K
- Azeem AhsanCrest Hill$6K
- Adeela CheemaChicago$5K
- Alex SanchezElgin$5K
- Seong ChinGlenview$4K
- Thomas CozziArlington Heights$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.